The earnings call highlighted significant growth and strategic initiatives such as the Metsera collaboration and the launch of CREXONT, contributing to a positive outlook. However, challenges such as the upcoming loss of exclusivity for Rytary and increased interest expenses were noted, though they are being mitigated by other growth drivers.

Company Guidance

During Amneal Pharmaceuticals' Third Quarter 2024 Earnings Call, the company provided robust guidance reflecting strong financial and operational performance. Revenue for Q3 grew by 13% to $702 million, with the generics segment contributing $427 million, a 9% increase driven by new product launches generating $35 million. The Specialty segment saw a 19% rise, reaching $116 million in revenue, with the Parkinson's franchise, including the newly launched CREXONT, significantly contributing. Adjusted EBITDA for the quarter was $158 million, with a 15% growth excluding a $20 million milestone payment related to the licensing of a biosimilar to Xolair. The company highlighted an expected reduction in net leverage to 4x by year-end 2024, aiming for further reduction to 3x in coming years. Looking ahead, Amneal anticipates continued growth across its diversified segments, including generics, injectables, biosimilars, and specialty products, with strategic investments in areas like GLP-1 manufacturing, which is poised to support future expansion into the global obesity market.

Strong Q3 Revenue Growth

Revenues grew 13% to $702 million with continued growth across all business segments. Generics grew 9% to $427 million, and Specialty segment revenues grew 19% to $116 million.

Metsera Collaboration

Amneal entered the global obesity space with a collaboration with Metsera, a biotech company focused on weight loss medicines, marking a significant milestone for Amneal.

CREXONT Launch

The launch of CREXONT, a new treatment for Parkinson's disease, was successful, with early indicators of commercial uptake being positive.

Healthcare Distribution Business Growth

The healthcare distribution business continues to deliver double-digit growth, expecting over $700 million in revenue in 2025.

Debt Reduction

Amneal reduced net leverage to 4.2x at the end of September 2024 and expects to finish the year at about 4x, one year ahead of their original target.

---

Amneal Pharmaceuticals (AMRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AMRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 27, 2025	2024 (Q4)	0.15 / -	0.14	―	―	―
Nov 08, 2024	2024 (Q3)	0.13 / 0.16	0.19	-15.79% (-0.03)
Aug 09, 2024	2024 (Q2)	0.15 / 0.16	0.19	-15.79% (-0.03)
May 03, 2024	2024 (Q1)	0.09 / 0.14	0.12	16.67% (+0.02)
Mar 01, 2024	2023 (Q4)	0.09 / 0.14	0.23	-39.13% (-0.09)
Nov 07, 2023	2023 (Q3)	0.13 / 0.19	0.14	35.71% (+0.05)
Aug 04, 2023	2023 (Q2)	0.10 / 0.19	0.19	0.00% (0.00)
May 05, 2023	2023 (Q1)	0.10 / 0.12	0.12	0.00% (0.00)
Mar 02, 2023	2022 (Q4)	0.21 / 0.23	0.18	27.78% (+0.05)
Nov 04, 2022	2022 (Q3)	0.18 / 0.14	0.21	-33.33% (-0.07)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

AMRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 08, 2024	$8.61	$8.73	+1.39%
Aug 09, 2024	$7.77	$7.65	-1.54%
May 03, 2024	$6.21	$6.76	+8.86%
Mar 01, 2024	$5.52	$5.47	-0.91%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---